HSINCHU, Taiwan — A Taiwanese vaccine manufacturer is aiming to market by 2022 a dengue vaccine that it says would not pose the same risks as the world’s only currently available vaccine Dengvaxia. The development of the dengue vaccine is one of the thrusts currently being pursued by the Taiwanese government under its New Southbound Policy, an economic tack that targets the Philippines and other Indo-Pacific countries. Deng said the TV003 vaccine developed by MVC together with the United States National Institutes of Health will be more effective than Dengvaxia because it would use a different genetic backbone structure. Dengvaxia uses a yellow fever virus vaccine as its genetic backbone, while TV003 uses a dengue virus backbone, he said. TV003 is currently in phase 3 clinical trials, which means that it is in the last stage of research before it could be ready for the market.

Source: Philippine Daily Inquirer May 07, 2018 07:52 UTC